ANZCTR - Registration

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial registered on ANZCTR

Registration number

ACTRN12616001307493

Ethics application status

Approved

Date submitted

4/08/2016

Date registered

19/09/2016

Date last updated

10/12/2020

Date data sharing statement initially provided

25/07/2019

Type of registration

Prospectively registered

Titles & IDs

Public title

A trial to investigate the different experiences of first time blood donors over 30 years of age who donate whole blood or who donate plasma by apheresis.

Scientific title

A vanguard multicentre, step wedged cluster randomised trial to assess the tolerability of plasmapheresis versus whole blood in first time donors before expansion to a national roll out

Secondary ID [1]

None

Universal Trial Number (UTN)

U1111-1185-7095

Trial acronym

ADOPT

Linked study record

Health condition

Health condition(s) or problem(s) studied:

Blood Donation

Condition category

Condition code

Other

Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

The study will compare the feasibility, tolerability and acceptability of offering New Donors (blood donors who have no record of having donated previously in Australia) aged between 30 years and 70 the option to choose between two donation types (1) whole blood OR (2) Plasma by Apheresis

Allocation:
a. Inbound Calls: New Donors who meet the inclusion criteria who book appointments at one of the 10 participating Donor Collection Centres via the National Call Centre (NCC) will be offered by a call centre agent the choice to donate whole blood or Plasma by apheresis
b. Outbound Calls: New Donors who meet the inclusion criteria who book appointments at one of the 10 participating Donor Collection Centres via the Blood Service Website will be contacted by a NCC agent and offered the choice to donate whole blood or Plasma by apheresis
c. Walk Ins: New Donors who meet the inclusion criteria who present at one of the 10 participating Donor Collection Centres will be offered the choice to donate whole blood or Plasma by apheresis by Donor Centre Staff.

Apheresis is the process of collecting blood components, like plasma using a cell separating machine. During a plasma donation, blood is drawn from the donation arm by a pump into a sterile single use disposable kit inside the cell separating machine. Inside the apheresis machine there is a blood processing chamber that centrifuges the blood, separating it into layers. Red cells are the heaviest and sit at the bottom, platelets and white cells are in the middle and plasma is at the top as it is the lightest. The apheresis machine is programmed to detect the plasma and divert it into a collection bag with the rest of the blood given back to the donor (red cells, white cells and platelets). This cycle is repeated until the desired collection volume is achieved. A small amount of citrate anticoagulant is mixed with each withdrawal of blood to prevent clotting. This is controlled by the cell separator. The anticoagulant works by inactivating calcium, which is require for clotting to occur. The donor will receive a small amount of anticoagulant as it is returned with the components that are not being collected. The cell separator also infuses 500ml of saline solution to the donor, to aid in the replacement of fluid.

The plasma collection volume for new donors is 13% of their Total blood Volume(TBV) capped at 750ml. TBV is estimated using the modified Nadler's equation

The plasma donation is collected over 45minutes, The entire donation process including registration, interview and refreshment time after donations usually takes around 1.5 hours

Intervention code [1]

Other interventions

Comparator / control treatment

Control: Whole Blood Donation.
Intervention: Plasmapheresis as a first donation type

Currently the Australian Guidelines for Selection of Blood Donors states that all blood donors must have donated at least 1 whole blood donation prior to being offered the choice to donate plasma by apheresis. Therefore Plasmapheresis as a first donation type is the intervention under investigation

Control group

Active

Outcomes

Primary outcome [1]

Retention rates (rates of return for subsequent donations) between new donors who donate whole blood and new donors who donate plasma by apheresis.

Data will be obtained through linkage to Blood Service Records

Timepoint [1]

6 months from the initial donation date

Secondary outcome [1]

Difference between whole blood and plasma groups vasovagal reactions.
Assessment of Vasovagal Reactions (VVRs) follows the International Society of Blood Transfusion (ISBT) guidelines for surveillance of complications related to Blood Donation.

Vasovagal reactions are self reported by donors or observed by attending donor centre staff. Vasovagal reactions are divided in two main subgroups
1. Without loss of consciousness (LOC) or
2. With loss of consciousness (LOC)

and further assessed based on time from symptom onset to time of full recovery, reported by donor or a attending blood service staff member(s)

Timepoint [1]

7 days post initial donation date

Secondary outcome [2]

Difference between whole blood and plasma groups Blood Donor Reaction Inventory (BDRI) scores.

Donors will rate on a Likert Scale 1-5, How they feel post donation in the following 4 symptom areas Faintness, Dizziness, Weakness and Light Headedness

Timepoint [2]

7 days post initial donation date

Secondary outcome [3]

Difference between whole blood and plasma groups in donor satisfaction as reported via study specific survey

Timepoint [3]

7 days post initial donation date

Secondary outcome [4]

Difference between whole blood and plasma groups in intention to donate in the future as reported via study specific survey

Timepoint [4]

7 days post initial donation date

Secondary outcome [5]

Difference between whole blood and plasma groups in retention at 12 months

Timepoint [5]

12 months post initial donation date

Secondary outcome [6]

Difference between whole blood and plasma groups in retention at 24 months

Timepoint [6]

24 months post initial donation date

Eligibility

Key inclusion criteria

Cluster (Blood Collection Centre)
Inclusion Criteria
1. Sufficient size to recruit 20 new donors a month over a 6- 7 month period and
2. a historical measure over a 18 month period (1/1/2014 to 31/06/2015) of
a) Greater than 10% first time whole blood donors converted to plasma
b) Greater than a 60% return rate for plasma to plasma donations
c) Greater than a 55% total retention rate for all donation types (WB, PLS, PLT)

Participant (Blood Donor)
Inclusion Criteria
1. Adults 30 years or over and less than 71 years
2. New Donor (someone who has never registered to donate)
3. Generally eligible for blood donation as per the current GSBD
4. Written consent for General Donation and written consent for Apheresis for plasma
donations.

Minimum age

30 Years

Maximum age

70 Years

Sex

Both males and females

Can healthy volunteers participate?

Yes

Key exclusion criteria

Cluster (Blood Collection Centre)
Exclusion Criteria
1. Participation in another research study (R&D or Marketing) that may interfere with donor
recruitment and the outcomes under investigation
2. Donor Services Leadership team consider the donor centre not appropriate for participation (e.g.: centre undergoing renovations, relocation)

Participant (Blood Donor)
Exclusion Criteria
1. Not eligible for any type of blood donation as per the current Guidelines for Selection of Blood Donors (GSBD)
2. Participation in a concurrent interventional medical investigation or clinical trial. Participants in observational, natural history and/ or epidemiological studies not involving an intervention are eligible. Participation in another Blood Service study at the time of donation is not permitted.
3. Vein unable to be palpated under pressure (BP cuff, tourniquet) during interview and in
donation chair

Study design

Purpose of the study

Prevention

Allocation to intervention

Randomised controlled trial

Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)

Allocation is not Concealed

Methods used to generate the sequence in which subjects will be randomised (sequence generation)

Donor Collection Centres (Cluster) will be randomised via a Simple randomisation scheme using computer software

Masking / blinding

Open (masking not used)

Who is / are masked / blinded?

Intervention assignment

Other

Other design features

Step Wedged Cluster Randomised Trial - Each participating donor collection centre will be randomised to commence the intervention (offer of plasma apheresis in first time donors) at a specific time point during the 7 month recruitment phase.

Phase

Not Applicable

Type of endpoint/s

Safety/efficacy

Statistical methods / analysis

Recruitment

Recruitment status

Completed

Date of first participant enrolment

Anticipated

3/10/2016

Actual

3/10/2016

Date of last participant enrolment

Anticipated

Actual

4/06/2017

Date of last data collection

Anticipated

4/12/2019

Actual

4/12/2019

Sample size

Target

1400

Accrual to date

Final

3035

Recruitment in Australia

Recruitment state(s)

NSW,QLD,SA,WA,VIC

Funding & Sponsors

Funding source category [1]

Charities/Societies/Foundations

Name [1]

Australian Red Cross Blood Service

Address [1]

National Office
Level 3, 417 St Kilda Rd
Melbourne VIC 3004
Australia

Country [1]

Australia

Primary sponsor type

Charities/Societies/Foundations

Name

Australian Red Cross Blood Service

Address

National Office
Level 3, 417 St Kilda Rd
Melbourne VIC 3004
Australia

Country

Australia

Secondary sponsor category [1]

None

Name [1]

Address [1]

Country [1]

Ethics approval

Ethics application status

Approved

Ethics committee name [1]

Australian Red Cross Blood Service Ethics Committee

Ethics committee address [1]

C/- Sydney Processing Centre
17 O'Riordan St
Alexandria NSW 2015

Ethics committee country [1]

Australia

Date submitted for ethics approval [1]

10/06/2016

Approval date [1]

02/08/2016

Ethics approval number [1]

Summary

Brief summary

Global demand for plasma-derived products including intravenous immunoglobulin (IVIg) continues to grow steadily. In contrast, medical advances and improvements in patient blood management have decreased requirements for red cell products. With less collections required to meet red cell inventory, the amount of fractionated plasma available from whole blood donations has been reduced. These factors have shifted donor centre operations from a primary focus on whole blood collections to an increased effort to recruit and retain plasmapheresis donors to meet future demand.

Australian Blood Service policy currently requires that blood donors give at least one whole blood donation before entering the plasmapheresis programme. The rationale behind this policy has been to determine donor suitability for apheresis donation (e.g. blood type, vein suitability) and to minimise vasovagal reactions and resulting donor drop-outs and deferrals. Similar policies for recruitment to plasmapheresis donation panels exist overseas with only the United States and the United Kingdom Blood Services permitting first-appointment apheresis donation. Consequently, little data exists regarding tolerability and donor acceptance of first-attendance plasma donation – particularly for voluntary non-remunerated blood donors.

With improvements in plasmapheresis safety (e.g. saline compensation), and concern over iron depletion among whole blood donors, a review of Australian plasmapheresis donation policy is warranted. Importantly, there is no regulatory barrier to implementing first appointment plasmapheresis donation. 

If tolerable and acceptable to donors, first-attendance plasmapheresis donation could help to:
1. Increase the plasmapheresis panel and overall collections of plasma for fractionation
2. Reduce the number of first attendance red cell deferrals
3. Reduce reliance on fractionated whole blood donations for collection of plasma

Trial website

Trial related presentations / publications

Public notes

Contacts

Principal investigator

Name

Prof David Irving

Address

Australia Red Cross Blood Service
Sydney Processing Centre
17 O'Riordan St
Alexandria NSW 2015

Country

Australia

Phone

+61 2 9234 2398

Fax

dirving@redcrossblood.org.au

Contact person for public queries

Name

Elizabeth Knight

Address

Australia Red Cross Blood Service
Sydney Processing Centre
17 O'Riordan St
Alexandria NSW 2015

Country

Australia

Phone

+61 2 9234 2386

Fax

BS_ClinicalTrials@redcrossblood.org.au

Contact person for scientific queries

Name

Barbara Bell

Address

Australia Red Cross Blood Service
Sydney Processing Centre
17 O'Riordan St
Alexandria NSW 2015

Country

Australia

Phone

+61 2 9234 2296

Fax

BS_ClinicalTrials@redcrossblood.org.au

Data sharing statement

Will individual participant data (IPD) for this trial be available (including data dictionaries)?

No/undecided IPD sharing reason/comment

What supporting documents are/will be available?

No Supporting Document Provided

Results publications and other study-related documents

Documents added manually

No documents have been uploaded by study researchers.

Documents added automatically

Source	Title	Year of Publication	DOI
Embase	Offering new and returned donors the option to give plasma: implications for donor retention and donor adverse events.	2021	https://dx.doi.org/10.1111/vox.12977

N.B. These documents automatically identified may not have been verified by the study sponsor.

Trial Review

Registering a new trial?

Documents added manually

Documents added automatically